Does Dose-dense Chemotherapy Improve Outcomes for Patients With High-risk Early Breast Cancer?

Share this content:
Dose-dense chemotherapy is not associated with an improvement in recurrence-free survival among patients with early-stage, high-risk breast cancer.
Dose-dense chemotherapy is not associated with an improvement in recurrence-free survival among patients with early-stage, high-risk breast cancer.

Dose-dense chemotherapy, a method of administering chemotherapy at shorter intervals to decrease toxic effects, is not associated with an improvement in recurrence-free survival among patients with early-stage, high-risk breast cancer, according to a study published in JAMA.1

Dose-dense chemotherapy regimens yield inconsistent drug safety, efficacy, and pharmacokinetic results. The objective of this study was to analyze the effects of dose-dense chemotherapy vs traditional therapy this patient population.

In this phase 3 clinical study (Clinicaltrials.gov Identifier: NCT00798070), researchers analyzed 2017 patients who had resected invasive breast cancer and had an Eastern Cooperative Oncology Group (ECOG) status score of 0 or 1. Efficacy endpoints included breast cancer recurrence-free survival (BCRFS), distant disease-free survival (DDFS), event-free survival (EFS), and overall survival (OS).

Although BCRFS rate for dose-tailored therapy vs conventional dosing method were not significantly different (hazard ratio, 0.79; 95% CI 0.61-1.01; P = 0.06), EFS rates were significantly higher for tailored dose group (hazard ratio, 0.79; 95% CI 0.63-0.99; P = 0.04).

The dose-tailored study arm displayed more grade 3 or 4 adverse effects, such as fatigue and neutropenic infections, than the control group. There were also more quality of life measure reductions in the dose-tailored group than the control group.

RELATED: Updated Recommendations for Intraoperative Radiation Therapy in Breast Cancer

According to the study's authors, dose-tailored chemotherapy may not improve outcomes over conventional chemotherapy among patients with high-risk, early-stage breast cancer.

Reference

  1. Foukakis T, von Minckwitz G, Bengtsson NO, et al. Effect of tailored dose-dense chemotherapy vs standard 3-weekly adjuvant chemotherapy on recurrence-free survival among women with high-risk early breast cancer: A randomized clinical trial. JAMA. 2016;316(18):1888-96. doi: 10.1001/jama.2016.15865

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs